{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:37:22Z","timestamp":1792748242796,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03827-6","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:37:17Z","timestamp":1792744637000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B\u00a0Cell Lymphoma in the United States"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7555-8736","authenticated-orcid":false,"given":"Kristen A.","family":"Deger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven L.","family":"Klijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado","family":"Franco-Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja V.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"5","key":"3827_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed\/refractory diffuse large B\u00a0cell lymphoma. Br J Haematol. 2018;182(5):633\u201343.","journal-title":"Br J Haematol"},{"key":"3827_CR2","unstructured":"American Cancer Society. Key statistics for non-Hodgkin lymphoma. https:\/\/www.cancer.org\/cancer\/types\/non-hodgkin-lymphoma\/about\/key-statistics.html. Accessed Apr 27, 2026."},{"key":"3827_CR3","unstructured":"American Cancer Society. Types of B-cell lymphoma. https:\/\/www.cancer.org\/cancer\/types\/non-hodgkin-lymphoma\/about\/b-cell-lymphoma.html. Accessed Apr 27, 2026."},{"key":"3827_CR4","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, et al.; on behalf of the ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v116\u201325.","journal-title":"Ann Oncol"},{"key":"3827_CR5","unstructured":"Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975\u20132016, National Cancer Institute. Bethesda, MD, based on November 2018 SEER data submission, posted to the SEER website, April 2019. https:\/\/seer.cancer.gov\/csr\/1975_2016\/. Accessed Apr 27, 2026."},{"key":"3827_CR6","doi-asserted-by":"crossref","unstructured":"Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B-cell lymphoma. South Asian J Cancer. 2014;3(1):66\u201370.","DOI":"10.4103\/2278-330X.126531"},{"key":"3827_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW. Relapsed\/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498\u2013505.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3827_CR8","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-Cell Lymphomas V.4.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed September 15, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN\u2009=\u2009National Comprehensive Cancer Network\u00ae (NCCN\u00ae)."},{"issue":"1","key":"3827_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2015.213","volume":"51","author":"E Van Den Neste","year":"2016","unstructured":"Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"3827_CR10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","volume":"20","author":"M Hamadani","year":"2014","unstructured":"Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B\u00a0cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(11):1729\u201336.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"3827_CR11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase\u00a03 TRANSFORM study. Blood. 2023;141(14):1675\u201384.","journal-title":"Blood"},{"key":"3827_CR12","doi-asserted-by":"crossref","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al.; for All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640\u201354.","DOI":"10.1056\/NEJMoa2116133"},{"issue":"2","key":"3827_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148\u201357.","journal-title":"N Engl J Med"},{"issue":"9","key":"3827_CR14","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/bloodadvances.2025019303","volume":"10","author":"M Kamdar","year":"2026","unstructured":"Kamdar M, Solomon SR, Arnason JE, et al. Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM. Blood Adv. 2026;10(9):2962\u20136.","journal-title":"Blood Adv"},{"issue":"5","key":"3827_CR15","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s12325-023-02444-x","volume":"40","author":"C Parker","year":"2023","unstructured":"Parker C, Liu FF, Deger KA, et al. Cost-effectiveness of lisocabtagene maraleucel versus axicabtagene ciloleucel and tisagenlecleucel in the third-line or later treatment setting for relapsed or refractory large B-cell lymphoma in the United States. Adv Ther. 2023;40(5):2355\u201374.","journal-title":"Adv Ther"},{"key":"3827_CR16","doi-asserted-by":"crossref","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM; on behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20131. Med Decis Making. 2012;32(5):667\u201377.","DOI":"10.1177\/0272989X12454577"},{"issue":"S2","key":"3827_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/hon.3164_332","volume":"41","author":"F Morschhauser","year":"2023","unstructured":"Morschhauser F, Ghesquieres H, Kamdar M, et al. Comparison of overall survival of lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) adjusting for crossover in second-line (2L) R\/R large B-cell lymphoma. Hematol Oncol. 2023;41(S2):451\u20132.","journal-title":"Hematol Oncol"},{"key":"3827_CR18","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1182\/blood-2021-148948","volume":"138","author":"JS Abramson","year":"2021","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Two-year follow-up of TRANSCEND NHL 001, a multicenter phase\u00a01 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL). Blood. 2021;138(suppl 2):2840.","journal-title":"Blood"},{"issue":"suppl 1","key":"3827_CR19","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1182\/blood-2021-148078","volume":"138","author":"CA Jacobson","year":"2021","unstructured":"Jacobson CA, Locke FL, Ghobadi A, et al. Long-term (\u22654\u00a0year and \u22655\u00a0year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL). Blood. 2021;138(suppl 1):1764.","journal-title":"Blood"},{"issue":"10","key":"3827_CR20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase\u00a02 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"key":"3827_CR21","unstructured":"National Institute for Health and Care Excellence. NICE DSU Technical Support Document 21: Flexible methods for survival analysis. https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/flexible-methods-survival-analysis. Accessed Apr 27, 2026."},{"key":"3827_CR22","unstructured":"National Institute for Health and Care Excellence (NICE). Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy [TA895]. https:\/\/www.nice.org.uk\/guidance\/ta895\/chapter\/1-Recommendations. Accessed Apr 27, 2026."},{"key":"3827_CR23","unstructured":"National Institute for Health and Care Excellence (NICE). Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies [TA872]. https:\/\/www.nice.org.uk\/guidance\/ta872. Accessed Apr 27, 2026."},{"key":"3827_CR24","unstructured":"National Institute for Health and Care Excellence (NICE). Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25\u00a0years and under [TA975]. https:\/\/www.nice.org.uk\/guidance\/ta975. Accessed Apr 27, 2026."},{"issue":"6","key":"3827_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2023.103828","volume":"62","author":"I Pessach","year":"2023","unstructured":"Pessach I, Nagler A. Leukapheresis for CAR-T\u00a0cell production and therapy. Transfus Apher Sci. 2023;62(6):103828.","journal-title":"Transfus Apher Sci"},{"key":"3827_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V, et al. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol. 2023;14:1303935.","journal-title":"Front Immunol"},{"issue":"10","key":"3827_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"issue":"27","key":"3827_CR28","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390.","journal-title":"J Clin Oncol"},{"issue":"24","key":"3827_CR29","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1200\/JCO-25-00399","volume":"43","author":"M Kamdar","year":"2025","unstructured":"Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase\u00a0III TRANSFORM study. J Clin Oncol. 2025;43(24):2671\u20138.","journal-title":"J Clin Oncol"},{"key":"3827_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"3827_CR31","unstructured":"Social Security Administration. Period life table, 2019, as used in the 2022 trustees report. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6_2019_TR2022.html. Accessed Apr 27, 2026."},{"issue":"10","key":"3827_CR32","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP, et al. Event-free survival at 24\u00a0months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066\u201373.","journal-title":"J Clin Oncol"},{"key":"3827_CR33","unstructured":"BREYANZI\u00ae (lisocabtagene maraleucel) [package insert]. Bothell, WA: Juno Therapeutics Inc., a Bristol-Myers Squibb Company; February 2026."},{"key":"3827_CR34","unstructured":"YESCARTA\u00ae (axicabtagene ciloleucel) [package insert]. Santa Monica, CA: Kite Pharma, Inc.; February 2026."},{"key":"3827_CR35","unstructured":"Bristol Myers Squibb. Data on file. TRANSFORM: October 23, 2023 data cutoff."},{"issue":"8","key":"3827_CR36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"AS Pickard","year":"2019","unstructured":"Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931\u201341.","journal-title":"Value Health"},{"issue":"3","key":"3827_CR37","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803\u201316.","journal-title":"Qual Life Res"},{"issue":"3","key":"3827_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s41669-021-00316-0","volume":"6","author":"TA Howell","year":"2022","unstructured":"Howell TA, Matza LS, Jun MP, Garcia J, Powers A, Maloney DG. Health state utilities for adverse events associated with chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Pharmacoecon Open. 2022;6(3):367\u201376.","journal-title":"Pharmacoecon Open"},{"key":"3827_CR39","unstructured":"US Bureau of Labor Statistics. Consumer Price Index (CPI) Databases. https:\/\/www.bls.gov\/cpi\/data.htm. Accessed Apr 27, 2026."},{"issue":"suppl 2","key":"3827_CR40","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.jtct.2025.12.078","volume":"32","author":"N Denlinger","year":"2026","unstructured":"Denlinger N, Schwede M, Yamshon S, et al. Real-world (RW) study of the effectiveness, safety, and health care resource utilization (HCRU) of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL) in the second-line (2L) treatment setting. Transplant Cell Ther. 2026;32(suppl 2):S50.","journal-title":"Transplant Cell Ther"},{"key":"3827_CR41","unstructured":"Bristol Myers Squibb. Data on file. Online survey of clinicians treating LBCL with CAR T-cell therapy and HSCT in the US, UK and the Netherlands."},{"key":"3827_CR42","unstructured":"Merative. Micromedex RED BOOK. https:\/\/www.merative.com\/documents\/brief\/micromedex-redbook-brochure. Accessed Apr 27, 2026."},{"key":"3827_CR43","unstructured":"Agency for Healthcare Research and Quality. HCUPnet inpatient stays, national statistics by Clinical Classification Software Refined (CCSR), principal diagnosis. All payer 2022 cost; inflated to 2026. https:\/\/datatools.ahrq.gov\/hcupnet\/. Accessed Apr 27, 2026."},{"key":"3827_CR44","unstructured":"Centers for Medicare & Medicaid Services. Medicare HO: CMS.gov. 2026 Q2 Medicare hospital outpatient PPS file. https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/hospital-outpatient. Accessed Apr 27, 2026."},{"key":"3827_CR45","unstructured":"Lopez E, Claxton G, Schwartz K, Rae M, Ochieng N, Neuman T. Comparing private payer and Medicare payment rates for select inpatient hospital services. https:\/\/www.kff.org\/medicare\/issue-brief\/comparing-private-payer-and-medicare-payment-rates-for-select-inpatient-hospital-services\/#:~:text=Private%20insurance%20payment%20rates%20were,much%20faster%20than%20Medicare%20rates. Accessed Apr 27, 2026."},{"issue":"24","key":"3827_CR46","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37(24):2105\u201319.","journal-title":"J Clin Oncol"},{"key":"3827_CR47","unstructured":"Institute for Clinical and Economic Review. Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_CAR_T_Final_Evidence_Report_032318.pdf. Accessed Apr 27, 2026."},{"key":"3827_CR48","unstructured":"Institute for Clinical and Economic Review. 2020\u20132023 value assessment framework. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf. Accessed Apr 27, 2026."},{"issue":"suppl 1","key":"3827_CR49","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.jval.2020.04.1592","volume":"23","author":"C Balmaceda","year":"2020","unstructured":"Balmaceda C, Abbott T, Espinoza MA. Pcn92 cost-effectiveness analysis of polatuzumab in combination with rituximab and bevacizumab for the treatment of patients with relapsed\/refractory diffuse large B-cell lymphoma. Value Health. 2020;23(suppl 1):S40.","journal-title":"Value Health"},{"issue":"11","key":"3827_CR50","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1080\/13696998.2020.1808981","volume":"23","author":"BP Cher","year":"2020","unstructured":"Cher BP, Gan KY, Aziz MIA, et al. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed\/refractory diffuse large B-cell lymphoma from Singapore\u2019s healthcare system perspective. J Med Econ. 2020;23(11):1321\u20139.","journal-title":"J Med Econ"},{"issue":"12","key":"3827_CR51","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","volume":"21","author":"JA Roth","year":"2018","unstructured":"Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238\u201345.","journal-title":"J Med Econ"},{"key":"3827_CR52","unstructured":"National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies: technology appraisal guidance [TA559]. https:\/\/www.nice.org.uk\/guidance\/ta559. Accessed Apr 27, 2026."},{"key":"3827_CR53","unstructured":"Scottish Medicines Consortium. Tisagenlecleucel 1.2 x 106 \u2013 6 x 108 cells dispersion for infusion (Kymriah\u00ae) [SMC2129]. https:\/\/scottishmedicines.org.uk\/media\/4132\/tisagenlecleucel-kymriah-final-jan-2019-for-website.pdf. Accessed Apr 27, 2026."},{"issue":"10254","key":"3827_CR54","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"1","key":"3827_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase\u00a01\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"8","key":"3827_CR56","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.clinthera.2021.06.011","volume":"43","author":"CZ Qi","year":"2021","unstructured":"Qi CZ, Bollu V, Yang H, Dalal A, Zhang S, Zhang J. Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States. Clin Ther. 2021;43(8):1300-19.e8.","journal-title":"Clin Ther"},{"issue":"5","key":"3827_CR57","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bjh.18335","volume":"198","author":"L Shargian","year":"2022","unstructured":"Shargian L, Raanani P, Yeshurun M, Gafter-Gvili A, Gurion R. Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: a systematic review and meta-analysis. Br J Haematol. 2022;198(5):838\u201346.","journal-title":"Br J Haematol"},{"issue":"19","key":"3827_CR58","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood.2022016747","volume":"140","author":"S Kambhampati","year":"2022","unstructured":"Kambhampati S, Saumoy M, Schneider Y, et al. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022;140(19):2024\u201336.","journal-title":"Blood"},{"key":"3827_CR59","doi-asserted-by":"crossref","unstructured":"Perales MA, Kuruvilla J, Snider JT, et al. The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: an economic evaluation of the ZUMA-7 trial. Transplant Cell Ther. 2022;28(11):750.e1\u2013.e6.","DOI":"10.1016\/j.jtct.2022.08.010"},{"issue":"2","key":"3827_CR60","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1182\/bloodadvances.2023011793","volume":"8","author":"JH Choe","year":"2024","unstructured":"Choe JH, Yu T, Abramson JS, Abou-El-Enein M. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv. 2024;8(2):484\u201396.","journal-title":"Blood Adv"},{"key":"3827_CR61","unstructured":"Practice Management Information Corporation. Usual, customary and reasonable (UCR) physician fees. In: Medical Fees Directory 2025. https:\/\/medicalcodingbooks.com\/p\/medical-fees-2025\/?srsltid=AU7gw4WMQPL6rhCrIHmvnJVQtcHXks5VRXHNIkjeHeeNFhOeX2Lb7zpk#fulldescription. Accessed Apr 27, 2026."},{"key":"3827_CR62","unstructured":"United States Food and Drug Administration. BLA 125643\/394 clinical review and evaluation: axicabtagene ciloleucel (Yescarta). https:\/\/fda.report\/media\/157687\/April-1-2022-Clinical-Review-and-Evaluation-YESCART_0.pdf. Accessed Apr 27, 2026."},{"key":"3827_CR63","unstructured":"Agency for Healthcare Research and Quality. HCUPnet inpatient stays, National statistics by Principal ICD-10 Procedure. Commercial Payer 2017 Cost; inflated to 2026. https:\/\/datatools.ahrq.gov\/hcupnet\/. Accessed Apr 27, 2026."},{"issue":"6","key":"3827_CR64","doi-asserted-by":"publisher","first-page":"75s","DOI":"10.1200\/JOP.2011.000469","volume":"8","author":"B Chastek","year":"2012","unstructured":"Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8(6):75s\u201380s.","journal-title":"J Oncol Pract"},{"issue":"12","key":"3827_CR65","doi-asserted-by":"publisher","first-page":"e2245956","DOI":"10.1001\/jamanetworkopen.2022.45956","volume":"5","author":"JH Choe","year":"2022","unstructured":"Choe JH, Abdel-Azim H, Padula WV, Abou-El-Enein M. Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma. JAMA Netw Open. 2022;5(12):e2245956.","journal-title":"JAMA Netw Open"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03827-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:37:23Z","timestamp":1792744643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03827-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":65,"alternative-id":["3827"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03827-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fei Fei Liu and Sven L. Klijn are employees of and hold stock in Bristol Myers Squibb. Kristen A. Deger, Conrado Franco-Villalobos, and Sonja V. Sorensen are employees of Thermo Fisher Scientific, which was contracted by Bristol Myers Squibb to perform this study. Matthew Lunning has served in a consulting or advisory role to Kite\/Gilead, Bristol Myers Squibb, AstraZeneca, Genentech, Fate Therapeutics, Ipsen, Recordati, Vittoria Biotherapeutics, Loxo Oncology, AbbVie, Pfizer, AstraZeneca, and Incyte Corporation; has received research funding from Fate Therapeutics; and the institution that he is employed by has received research funding from Curis.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study analyzed data derived from previously published trials involving CAR T\u00a0cell therapy. No new data were collected from any human participants or animals.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}